These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 21271362)
1. Stress and its role in sympathetic nervous system activation in hypertension and the metabolic syndrome. Lambert EA; Lambert GW Curr Hypertens Rep; 2011 Jun; 13(3):244-8. PubMed ID: 21271362 [TBL] [Abstract][Full Text] [Related]
2. Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications. Lambert GW; Straznicky NE; Lambert EA; Dixon JB; Schlaich MP Pharmacol Ther; 2010 May; 126(2):159-72. PubMed ID: 20171982 [TBL] [Abstract][Full Text] [Related]
3. The underlying mechanisms for development of hypertension in the metabolic syndrome. Yanai H; Tomono Y; Ito K; Furutani N; Yoshida H; Tada N Nutr J; 2008 Apr; 7():10. PubMed ID: 18416854 [TBL] [Abstract][Full Text] [Related]
5. The sympathetic nervous system alterations in human hypertension. Grassi G; Mark A; Esler M Circ Res; 2015 Mar; 116(6):976-90. PubMed ID: 25767284 [TBL] [Abstract][Full Text] [Related]
6. Stress, the sympathetic nervous system and hypertension. Kaplan NM J Human Stress; 1978 Sep; 4(3):29-34. PubMed ID: 690419 [TBL] [Abstract][Full Text] [Related]
9. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Esler M; Rumantir M; Wiesner G; Kaye D; Hastings J; Lambert G Am J Hypertens; 2001 Nov; 14(11 Pt 2):304S-309S. PubMed ID: 11721888 [TBL] [Abstract][Full Text] [Related]
10. Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Lambert E; Sari CI; Dawood T; Nguyen J; McGrane M; Eikelis N; Chopra R; Wong C; Chatzivlastou K; Head G; Straznicky N; Esler M; Schlaich M; Lambert G Hypertension; 2010 Sep; 56(3):351-8. PubMed ID: 20625075 [TBL] [Abstract][Full Text] [Related]
11. Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited. da Silva AA; do Carmo JM; Li X; Wang Z; Mouton AJ; Hall JE Can J Cardiol; 2020 May; 36(5):671-682. PubMed ID: 32389340 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Masuo K; Rakugi H; Ogihara T; Esler MD; Lambert GW Curr Diabetes Rev; 2010 Mar; 6(2):58-67. PubMed ID: 20034369 [TBL] [Abstract][Full Text] [Related]
13. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). Landsberg L J Hypertens; 2001 Mar; 19(3 Pt 2):523-8. PubMed ID: 11327624 [TBL] [Abstract][Full Text] [Related]
16. The etiology of hypertension in the metabolic syndrome part one: an introduction to the history, the concept and the models. Sharma V; McNeill JH Curr Vasc Pharmacol; 2006 Oct; 4(4):293-304. PubMed ID: 17073699 [TBL] [Abstract][Full Text] [Related]
17. High screening blood pressure is related to sympathetic nervous system activity and insulin resistance in healthy young men. Fossum E; Høieggen A; Reims HM; Moan A; Rostrup M; Eide I; Kjeldsen SE Blood Press; 2004; 13(2):89-94. PubMed ID: 15182111 [TBL] [Abstract][Full Text] [Related]
18. Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. Esler M; Lambert G; Brunner-La Rocca HP; Vaddadi G; Kaye D Acta Physiol Scand; 2003 Mar; 177(3):275-84. PubMed ID: 12608997 [TBL] [Abstract][Full Text] [Related]
19. Neural mechanisms and management of obesity-related hypertension. Esler MD; Eikelis N; Lambert E; Straznicky N Curr Cardiol Rep; 2008 Nov; 10(6):456-63. PubMed ID: 18950554 [TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of essential hypertension: an update. Saxena T; Ali AO; Saxena M Expert Rev Cardiovasc Ther; 2018 Dec; 16(12):879-887. PubMed ID: 30354851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]